Purpose: This study explores the effect of Vagus Nerve Stimulator (VNS) on Status Epilepticus (SE) in children with medically intractable epilepsy. Methods: Retrospective review was conducted in children with a history of at least two SE, who had VNS implantation and had at least one year follow up after the procedure. Results: Sixteen patients met inclusion/exclusion criteria. The median age of seizure onset and surgery was 1.3 years and 9.0 years, respectively. Prior to VNS implantation, 81% (13/16) of patients had one seizure per month when all seizure types were combined. 75% (12/16) of patients experienced one generalized convulsive seizure per month. The median number of SE prior to VNS was three (2-9), and 63% (10/16) had at least one SE during a year prior to implantation. The proportion of patients who did not have any SE one year after VNS implantation increased compared to the year prior (75% vs. 37%, p = 0.07). The seizure frequency decreased in a minority of patients when all seizure types were combined (20% at one year, p = 1.00, 44% at the last follow up, p = 0.55), but generalized convulsive seizure decreased in 69% of patients at one year (p = 0.01) and 75% of patients at last follow up (p = 0.01).
Introduction
Vagus Nerve Stimulator (VNS) has been used as an adjunctive treatment for intractable epilepsy in adults and children, has been reported as an effective acute treatment for refractory Status Epilepticus (SE), which is the most common pediatric neurological emergency with morbidity and mortality ranging from 1 to 16% [1, 2] [3, 4] . The actual mechanism of action of VNS remains unclear, but the thalamus and the limbic system are thought to be important based on changes in regional cerebral blood flow study during VNS stimulation [5] . This study explores the effect of VNS on SE and generalized convulsive seizures in children with medically intractable epilepsy.
Material and methods
Retrospective review was conducted in children, who had VNS implantation between 2011 and 2014 and had at least one year follow up after the procedure. The patients in this study had history of at least two SE prior to VNS implantation. The Children's Hospital of Pittsburgh is the tertiary children's hospital with level 4 comprehensive epilepsy center. The primary outcome was the presence or absence of SE during one year post-VNS implantation, which was compared to one year prior to VNS implantation. SE was defined as either 1) a seizure documented as status epilepticus by physicians, 2) a seizure persisting upon arrival to ED, or 3) a seizure longer than 10 min with active motor manifestations [3, 6, 7] . The patients were typically followed every two to four weeks for the initial three months and every one to three months thereafter for VNS adjustments. The change in seizure frequency was our secondary outcome and was analyzed at group level as well as at each patient level. Seizure frequency was collected as: 1) one seizure per week; 2) <one per week, but one per month; 3) <one seizure per month, but two per Abbreviations: SE, Status Epilepticus; VNS, Vagus Nerve Stimulator; AED, antiepileptic drug.year; 4) <two seizures per year. For statistical analysis at group level, seizure frequency was dichotomized between one per month and <one per month. This cutoff was chosen based on our typical practice to offer VNS [8] . Seizure frequency in each patient was classified as decreased, unchanged, or increased based on the change in category of seizure frequency. One year was chosen because VNS adjustment typically occurs over three to six months [2] . Seizure types were combined to determine total seizure frequency and were collected on each visit after VNS implantation. Generalized convulsive seizures and SE were collected and analyzed separately. Etiology was dichotomized into 'known' and 'unknown' based on the revised ILAE Classification [9] . Patients were classified as cognitively impaired if full scale IQ was <70. Epilepsy type was dichotomized between focal and generalized/ mixed/non-localizable [9] . Regarding VNS parameters, duty cycle (%) and output current (mA) were analyzed [2] . Data analysis was performed with Stata software version 10 (StataCorp LP, College Station, TX). A two-sided P value of <0.05 was considered statistically significant. Nonparametric tests were used due to small sample size: the primary outcome was analyzed using exact McNemar's test for comparing matched proportions, secondary outcomes were analyzed using the exact sign test for paired ordinal outcomes and Fisher's exact test for analyzing patient level characteristics. The association between seizure frequency change and these clinical variables were analyzed in binary fashion. This study was approved by our Institutional Review Board. (Table 1) 18/81(22%) patients, who had VNS implantation between year 2011 and 2014, had history of at least two SE. Two patients did not reach one year follow up; VNS was turned off within one month because of discomfort in one patient, and VNS was explanted secondary to infection in another. The final cohort consists of 16 patients (9 male). Two of them have been published previously [10] . The median age of seizure onset and surgery was 1.3 years and 9.0 years, respectively. The median follow up duration was 2.7 years. The majority (88%) had a known etiology, and cognitive impairment was common (69%). Over half of them (62.5%) were classified as having generalized/mixed/non-localizable epilepsy at the time of surgery. One patient had resective surgery prior to VNS. A median of four anti-epileptic drugs (AEDs) were trialed prior to VNS implantation .
Results

Clinical characteristics
Seizure frequency prior to implantation (Table 2)
Prior to VNS implantation, 81% (13/16) of patients had one seizure per month (all seizure types combined). 75% (12/16) of patients experienced one generalized convulsive seizure per month. The median number of SE prior to VNS was three (2 to 9), and 63% (10/16) had at least one SE in the year prior to VNS implantation .
Seizure frequency after implantation (Table 2)
At one year after VNS implantation and at the last follow up, the median output current was 1.75 mA (0.5-2.25 mA) and 2 mA (1.5-3 mA), median duty cycle was 25% (10-44%) and 44% (25-44%) respectively. There was a non-statistically significant decrease in the proportion of patients who had at least one SE within a year after VNS implantation relative to the year prior to VNS implantation (63% vs. 25%, p = 0.07): 3 of the 10 patients who had at least one SE in the year prior to VNS implantation experienced SE in the year after implantation, compared to 1 of the 
Discussion
Large cohorts of children with VNS therapy have been published, yet efficacy of VNS on specific seizure type and epilepsy syndrome remains limited [2, 11] . Among seizure types, generalized convulsive seizures and SE are especially important due to higher mortality and morbidity [6, 12] . Orosz et al reported improvement of 21.7% at 12 months and 29.3% at 24 months post-VNS in subset analysis of about 100 patients with predominantly generalized tonic-clonic seizures [11] . Our results cannot be directly compared with this study as they used a different definition for seizure improvement, but showed a similar trend of improvement at one year (69%) and at the last follow up (75%). The impact of VNS on status epilepticus was specifically studied on one study [4] . They reported eight adult patients with history of multiple episodes of SE with reduction of SE in 75% (6/8) of patients over a mean follow-up duration of four years. Our result showed a similar trend. Ten patients had SE within one year prior to VNS, and only three of them experienced SE within one year after VNS implantation. The study by Orosz et al reported the mean duration of epilepsy prior to VNS implantation in children was 8.3 years and were tried on mean of 6.9 AEDs prior to VNS implant [11] . Although not statistically significant, our result of decrease in the proportion of patients with SE after VNS implantation may suggest that VNS could be considered at an earlier stage in selected patients with intractable epilepsy. The strength and limitation of our study needs to be addressed. Our study has relatively long and consistent follow up. None of 18 eligible patients were excluded because of lack of sufficient follow up. The number of patients, who had multiple SE prior to VNS implantation, was higher (22%) at our institution than the general epilepsy population. However, this is clearly too small to explore the relation between clinical variables and VNS efficacy, or to evaluate true decrease in SE. Seizure frequency was collected categorically in our study, not as 50% or 90% reduction as in conventional clinical trials. We thought our approach was more practical in this patient population, as many of them had difficultto-count seizure types (e.g. absence and myoclonic). Our study was not controlled; therefore, we cannot exclude the possibility that concurrent AED adjustments would have impacted the outcome. However, this is less likely as patients had failed multiple AEDs before VNS implantation and we typically avoid AED adjustments during the first six months of VNS adjustment. It is also possible that seizure frequency was under-reported over time, including status epilepticus, although we assert that the treating epileptologist was aware of most, if not all, prolonged seizures or episodes of status epilepticus given more frequent and regular clinical follow up for VNS adjustment.
Conclusion
VNS appears to have favorable impact on SE and generalized convulsive seizures. This may be an area of further study in patients with intractable epilepsy, as these seizure types are associated with higher mortality and morbidity.
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